Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 335 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overweight With Diabetes Clear all
Completed No phase listed Observational

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

NCT00960765
View directory record Official record
Conditions
Obesity, Morbid, Diabetes Mellitus, Type 2, Gastric Bypass
Interventions
Not listed
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Results available

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

NCT04407234
View directory record Official record
Conditions
Overweight, Obesity, Diabetes Mellitus, Type 2
Interventions
Tirzepatide, Acetaminophen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Not listed Not applicable Interventional

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

NCT03058029
View directory record Official record
Conditions
Overweight, Diabetes, PreDiabetes, Obesity
Interventions
Gelesis200, Placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jun 25, 2026, 6:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Lifestyle Interventions for Long Term Diabetes Control

NCT00364312
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
diet and physical activity
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Jun 25, 2026, 6:41 PM EDT
Not yet recruiting Phase 3 Interventional

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803
View directory record Official record
Conditions
Weight Management
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

NCT05963594
View directory record Official record
Conditions
Dietary Supplement
Interventions
Oligomalt, maltodextrin
Dietary Supplement
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program

NCT00867425
View directory record Official record
Conditions
Obesity, Diabetes, Cardiovascular Disease
Interventions
Virtual Lifestyle Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 62 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Anti-inflammatory Effects of the Fiber

NCT02868788
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
dietary fiber, HFHC meal
Dietary Supplement · Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT06897475
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY3457263, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Behavioral Family Systems Therapy for Teens With Type 2 Diabetes

NCT05422807
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Childhood Obesity
Interventions
BFST for Teens with Type 2 Diabetes
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

NCT07215559
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

TRE With Physical Activity for Weight Management

NCT04978376
View directory record Official record
Conditions
Pre Diabetes, Overweight and Obesity
Interventions
Time restricted eating
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

NCT02307279
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Gelesis100, placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
25
States / cities
Anaheim, California • San Diego, California • Tustin, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Jun 25, 2026, 6:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

NCT06149793
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Empagliflozin, Placebo Control
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Active, not recruiting Early Phase 1 Interventional Results available

Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

NCT04881799
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Phentermine/Topiramate (Qsymia), Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 20 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Not yet recruiting Not applicable Interventional

Reset: Enhancing Weight Loss in a Digital Intervention

NCT07032571
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss, Health Behavior, Lifestyle Intervention
Interventions
Core Behavioral Weight Loss Intervention, Limit Red Zone Foods, Limit Eating Window, Increase Protein, Increase Fiber Intake
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Active, not recruiting Phase 3 Interventional

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

NCT07220759
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Cagrilintide, Placebo (matched to Cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 1 Interventional

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

NCT06105931
View directory record Official record
Conditions
type1diabetes, Obesity
Interventions
Hyperinsulinemic-euglycemic clamp, High Fat Mixed Meal Tolerance Test
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

NCT04184622
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
54
States / cities
Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity

NCT02060279
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Lifestyle intervention and carotenoid supplements, Lifestyle intervention and placebo
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
8 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Examining the Effects of Diet on Health With an Online Program

NCT01967992
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Behavioral: Low Carbohydrate, Ketogenic Diet, American Diabetes Association Diet, Mindfulness and Positive Affect Skills
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jun 25, 2026, 6:41 PM EDT